.Attribute Medication, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 study, trastuzumab deruxtecan (T-DXd) treatment of people along with HER2+ state-of-the-art breast cancer cells and energetic or even dependable human brain metastases showed regular intracranial activity and wide spread effectiveness of T-DXd.